A reference library for molecular identity, constituents and interpretation of scientific evidence.
Explore how compounds work and what the studies are uncovering.
Discover the scienceExplore the reference for each compound.
Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Molecular identity and scientific context.
Explore →Identifying a compound, understanding the type of evidence and recognizing its limits are separate steps.
For more information, contact info@aurevixpeptides.com.
BPC-157BPC-157 is studied for processes involved in tendon and connective-tissue repair, including collagen organization and cellular responses to injury. The potential application is tissue recovery, supported here by preclinical findings rather than established clinical benefits.
Read referenceGHK-CuGHK-Cu is investigated for collagen, extracellular-matrix remodeling and skin biology. These processes explain interest in skin and tissue applications, but results differ by experimental setting and cannot be transferred between topical and injectable formulations.
Read referenceNAD+NAD+ is a cofactor involved in cellular energy reactions and enzyme activity. Research examines its metabolism and related pathways; measuring NAD+ metabolites does not by itself demonstrate more energy or slower aging.
Read referenceRetatrutideRetatrutide combines GIP, GLP-1 and glucagon receptor activity. The cited phase II trial reported weight reductions that motivate further clinical study; its findings concern a particular investigational treatment and follow-up period.
Read referenceTesamorelinTesamorelin stimulates the GHRH pathway. Human studies in HIV-associated abdominal fat accumulation have measured reduced visceral fat; that specific finding should not be confused with general body-weight loss.
Read referenceTirzepatideTirzepatide combines GIP and GLP-1 receptor activity. Human trials have measured substantial weight reduction with specific medicines and treatment plans; individual outcomes and risks vary, and these results do not establish equivalence of other preparations.
Read reference